Cargando…

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants

Crizotinib is a small‐molecule, multitargeted tyrosine kinase inhibitor that exhibits decreased aqueous solubility at a higher pH. This open‐label, randomized, phase 1 study (NCT01549574) evaluated the effect of multiple doses of the proton pump inhibitor esomeprazole on the pharmacokinetics (PK) of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Huiping, O'Gorman, Melissa, Matschke, Kyle, Boutros, Tanya, Brega, Nicoletta, Tan, Weiwei, Bello, Akintunde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299459/ https://www.ncbi.nlm.nih.gov/pubmed/34825782 http://dx.doi.org/10.1002/cpdd.1032

Ejemplares similares

Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021)

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022)

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
por: de Man, Femke M., et al.
Publicado: (2019)

Effect of esomeprazole on the pharmacokinetics of carbamazepine
por: Medhi, Bikash, et al.
Publicado: (2011)

Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis
por: Ghebremariam, Yohannes T, et al.
Publicado: (2015)

Pharmacokinetics of Esomeprazole in Critically Ill Patients
por: Xu, Yanyan, et al.
Publicado: (2022)

Proton-Pump Inhibitor Utilization Associated With the Change to Nonpreferred Formulary Status for Esomeprazole in the TRICARE Formulary
por: Linton, Andrea, et al.
Publicado: (2009)

Esomeprazole and apixaban pharmacokinetic interactions in healthy rats
por: Jaber, Ali, et al.
Publicado: (2022)

Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole
por: Bae, Sungyeun, et al.
Publicado: (2021)

Esomeprazole-Induced Chest Pain: A Case of an Unexpected Serious Adverse Reaction to a Proton Pump Inhibitor
por: Radas, Melanija Ražov, et al.
Publicado: (2020)

Effects of Plasma Albumin on the Pharmacokinetics of Esomeprazole in ICU Patients
por: Tian, Hsin, et al.
Publicado: (2018)

The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing
por: Smith, Joe S., et al.
Publicado: (2023)

Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease
por: de Alwis, Natasha, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of esomeprazole and ranitidine during continuous venovenous hemodiafiltration
por: Fuhrmann, V, et al.
Publicado: (2013)

Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs
por: Cook, Emily K, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs
por: Seo, Do‐Hyun, et al.
Publicado: (2018)

Pharmacokinetics of esomeprazole in goats (Capra aegagrus hircus) after intravenous and subcutaneous administration
por: Fladung, Rachel, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Harmful Consequences of Proton Pump Inhibitors on Male Fertility: An Evidence from Subchronic Toxicity Study of Esomeprazole and Lansoprazole in Wistar Rats
por: Mumtaz, Namra, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects
por: Niazi, Mohammad, et al.
Publicado: (2012)

Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats
por: Kim, Tae Hwan, et al.
Publicado: (2018)

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
por: Perera, Vidya, et al.
Publicado: (2022)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
por: Perera, Vidya, et al.
Publicado: (2022)

The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor
por: Jones, R, et al.
Publicado: (2008)

Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life
por: Takeshima, Fuminao, et al.
Publicado: (2015)

Fabrication of Polymeric Hydrogels Containing Esomeprazole for Oral Delivery: In Vitro and In Vivo Pharmacokinetic Characterization
por: Ullah, Irshad, et al.
Publicado: (2023)

Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
por: Wedemeyer, Ralph-Steven, et al.
Publicado: (2014)

Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(®) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
por: Choi, YoonJung, et al.
Publicado: (2015)

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib
por: Ruiz-Garcia, Ana, et al.
Publicado: (2020)

Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics
por: Ward, Robert M., et al.
Publicado: (2013)

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs
por: Hwang, J.‐H., et al.
Publicado: (2017)

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2023)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients
por: Veerman, G. D. Marijn, et al.
Publicado: (2020)

Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor
por: Srivastava, Pratima
Publicado: (2012)

Crystallization of Esomeprazole Magnesium Water/Butanol Solvate
por: Skieneh, Jenna, et al.
Publicado: (2016)

Mandibular Osteonecrosis Associated with Antacid Therapy (Esomeprazole)
por: Marconcini, Simone, et al.
Publicado: (2019)

Complexity in Estimation of Esomeprazole and its Related Impurities’ Stability in Various Stress Conditions in Low-Dose Aspirin and Esomeprazole Magnesium Capsules
por: Reddy, Palavai Sripal, et al.
Publicado: (2013)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
por: Fujiwara, Yutaka, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6prr9mu3eotivf85mas8l6nl02